ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 537

Secukinumab, a Human Anti–Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial

Alice B. Gottlieb1, Philip J. Mease2, Iain B. McInnes3, Bruce Kirkham4, Arthur Kavanaugh5, Proton Rahman6, Peter Nash7, Luminita Pricop8, Jiacheng Yuan9, Hanno Richards10 and Shephard Mpofu11, 1Tufts Medical Center, Boston, MA, 2Swedish Medical Center and University of Washington, Seattle, WA, 3University of Glasgow, Glasgow, United Kingdom, 4Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, 5UCSD School of Medicine, La Jolla, CA, 6Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 7University of Queensland, Brisbane, Australia, 8Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, 9Novartis Pharmaceuticals Corporation, East Hanover, NJ, 10Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland, 11Novartis Pharma AG, Basel, Switzerland

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: monoclonal antibodies, psoriasis, Psoriatic arthritis, quality of life and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment I

Session Type: Abstract Submissions (ACR)

Background/Purpose

Reducing the burden of skin manifestations of psoriatic arthritis (PsA) is an important aspect of disease management. Secukinumab, a human anti–IL-17A monoclonal antibody, has demonstrated rapid and sustained efficacy in the treatment of psoriasis in phase 3 trials, including in the subset of patients (pts) with PsA. Here we present the effect of secukinumab on dermatological parameters in pts enrolled in FUTURE 1 (NCT01392326), the first phase 3 trial to evaluate the efficacy of IL-17A inhibition in pts with PsA.

Methods

Adults with moderate to severe PsA according to ClASsification of Psoriatic ARthritis criteria were randomized to a secukinumab 10 mg/kg intravenous (i.v.) loading dose at baseline (BL), Week (Wk) 2, and Wk 4, then either 75 mg subcutaneously (s.c.; 10 IV→75 SC) or 150 mg s.c. (10 IV→150 SC) every 4 wks from Wk 8, or placebo (PBO) on the same i.v. and s.c. schedules. Assessments of psoriasis burden included 75% and 90% improvement in Psoriasis Area and Severity Index (PASI 75/90), Investigator’s Global Assessment (modified 2011) score of 0 or 1 (IGA 0/1), target lesion score (TLS), modified Nail Psoriasis Severity Index (mNAPSI), and the Dermatology Life Quality Index (DLQI). The effect of treatment on high-sensitivity C-reactive protein (hsCRP) levels, a marker of skin and joint inflammation, was also monitored.

Results

From the full analysis set (FAS) of 606 pts, 325 (53.6%) had psoriasis affecting ≥ 3% of body surface area at BL (psoriasis subset), 510 (84.2%) had a psoriatic target lesion ≥ 2 cm in diameter (TLS subset) and 435 (71.8%) had nail involvement (nail subset). Improvements in dermatology parameters with secukinumab vs. PBO at Wk 24 are presented in the table. In the psoriasis subset, 10 IV→75 SC and 10 IV→150 SC significantly improved the proportion of PASI 75, PASI 90, and IGA 0/1 responders vs. PBO at Wk 24, and provided clinically meaningful improvement (≥ 4-point change from BL) in DLQI, with most pts having a decline in DLQI score from > 10 (severe) at BL to < 4 at Wk 24. Pts in the TLS subset experienced a rapid (from Wk 1) and significant improvement in TLS with secukinumab vs. PBO at Wk 24, while mNAPSI was significantly improved with secukinumab in the nail subset. hsCRP values were significantly lower with secukinumab vs. PBO from Wk 1 through Wk 24 (FAS).The improvements in dermatological parameters observed with secukinumab at Wk 24 were sustained through Wk 52.

Table. Effect of treatment on skin and involvement at Week 24

BL and Wk 24 Data

Secukinumab

10 mg/kg IV → 75 mg SC

Secukinumab

10 mg/kg IV → 150 mg SC

Placebo

aPASI Responses

    BL score

    PASI 75/90, % responders

6.4

64.8* / 49.1*

9.2

61.1* / 45.4*

8.9

8.3 / 3.7

aIGA 0/1,  % responders

54.6*

49.1*

3.7

bTLS

     BL

     Mean change from BL

5.5

–4.46*

6.0

–4.64*

6.1

–1.31

cmNAPSI

     BL

     Mean change from BL

18.6

–12.3*

18.7

–10.9*

17.5

–4.1

aDLQI total score

     BL

     Mean change from BL

11.2

–7.87*

12.6

–8.80*

12.5

0.70

*P < 0.0001 vs. placebo; aData from patients with psoriasis affecting ≥ 3% of body surface area at BL (n=325); bTLS data from patients with psoriatic target lesion ≥ 2 cm in diameter (n=510); cData from patients with nail psoriasis (n=435).

BL, baseline; DLQI, Dermatology Life Quality Index;IGA, Investigator’s Global Assessment; IV, intravenous; mNAPSI, modified Nail Psoriasis Severity Index; PASI, Psoriasis Area and Severity Index; SC, subcutaneous; TLS, target lesion score

Conclusion

This is the first phase 3 trial in pts with active PsA to demonstrate that selective IL-17A inhibition with secukinumab significantly reduces the severity of plaque and nail psoriasis and improves quality of life in those pts with a significant concomitant psoriasis burden in addition to their joint disease.


Disclosure:

A. B. Gottlieb,

Consulting fees from Amgen Inc., Astellas, Akros, Centocor (Janssen), Inc. Celgene Corp., Bristol Myers Squibb Co., Beiersdorf, Inc., Abbott Labs. (Abbvie), DUSA, TEVA, Actelion, UCB, Novo Nordisk, Novartis, Dermipsor Ltd., Incyte, Pfizer, Canfite, Lilly,,

5,

Advisory Board Agreements: Amgen Inc., Astellas, Akros, Centocor (Janssen), Inc. Celgene Corp., Bristol Myers Squibb Co., Beiersdorf, Inc., Abbott Labs. (Abbvie), DUSA, TEVA, Actelion, UCB, Novo Nordisk, Novartis, Dermipsor Ltd., Incyte, Pfizer, Canfite, ,

9,

Research/Educational Grants (paid to Tufts Medical Center): Centocor (Janssen), Amgen, Abbott (Abbvie), Novartis, Celgene, Pfizer, Lilly, Coronado, Levia, Merck,

2;

P. J. Mease,

Research grants from AbbVie, Amgen, Biogen Idec, BMS, Celgene, Crescendo, Janssen, Lilly, Merck, Novartis, Pfizer, UCB, and Vertex,

2,

Consulting fees from: AbbVie, Amgen, Biogen Idec, BMS, Celgene, Covagen, Crescendo, Janssen, Lilly, Merck, Novartis, Pfizer, UCB, and Vertex,

5,

Speakers’ bureau for AbbVie, Amgen, Biogen Idec, BMS, Crescendo, Janssen, Lilly, Pfizer, and UCB ,

8;

I. B. McInnes,

Consulting fees from Novartis, Amgen, Janssen, BMS, Pfizer, UCB, Abbvie, Celgene and Lilly,

5;

B. Kirkham,

Research grants from AbbVie and UCB,

2,

Consulting fees from Novartis, AbbVie, BMS, Lilly, and MSD,

5,

Speakers’ bureau for BMS, MSD, and UCB ,

8;

A. Kavanaugh,

Consulting fees from Novartis,

5;

P. Rahman,

Consulting fees from Abbott, AbbVie, Amgen, BMS, Celgene, Janssen, Novartis, Pfizer and Roche,

5;

P. Nash,

from Novartis, Abbvie, Roche, Pfizer, BMS, Janssen, and Celgene,

2,

Honoraria for lectures and advice from Novartis, Abbvie, Roche, Pfizer, BMS, Janssen, and Celgene,

9;

L. Pricop,

Employee of Novartis ,

3,

Novartis stock ,

1;

J. Yuan,

Employee of Novartis ,

3;

H. Richards,

Employee of Novartis ,

3;

S. Mpofu,

Novartis stock ,

1,

Employee of Novartis ,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/secukinumab-a-human-anti-interleukin-17a-monoclonal-antibody-significantly-reduces-psoriasis-burden-in-patients-with-psoriatic-arthritis-results-from-a-phase-3-randomized-controlled-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology